{"filings":[{"id":70282,"accession_number":"0001213900-26-055912","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2026-05-13T21:00:25+00:00","items":["1.01","3.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"iSpecimen prices $2.5M private placement at $5.12/share; regains Nasdaq minimum bid price compliance","event_type":"other_material","confidence":"high","bullets":["Private placement of 488,281 shares and pre-funded warrants for gross proceeds of ~$2.5M at $5.12 per share (or $5.1199 for warrants).","Net proceeds to be used for working capital, including up to $900,000 in marketing expenses.","Nasdaq confirmed compliance with $1.00 minimum bid price requirement on May 12, 2026 after 10 consecutive days above $1.","Annual meeting adjourned multiple times since Dec 31, 2025 due to lack of quorum; next adjourned to May 29, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93623,"accession_number":"0001213900-26-051013","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"iSpecimen effectuates 1-for-40 reverse stock split to regain Nasdaq compliance","event_type":"other_material","confidence":"high","bullets":["Reverse stock split effective 4:30 p.m. ET on April 27, 2026; trading on split-adjusted basis began April 28.","Shares outstanding reduced from 52,639,796 to approximately 1,316,032; no fractional shares issued (rounded up).","Board also ratified prior 1:20 reverse split (Sept 2024) via Certificate of Validation under Delaware law.","CUSIP changed to 45032V306; symbol remains ISPC on Nasdaq Capital Market.","Split intended to increase per-share price to attract institutional investors and meet minimum bid listing requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93622,"accession_number":"0001213900-26-042976","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"iSpecimen annual meeting adjourned five times due to lack of quorum; next attempt May 8, 2026","event_type":"other","confidence":"high","bullets":["Annual meeting convened Dec 31, 2025; quorum not present, adjourned.","Reconvened Jan 23, Feb 13, Mar 13, Apr 10, 2026; no quorum each time.","Next reconvened meeting scheduled for May 8, 2026 at 9:00 a.m. ET.","Record date remains Nov 3, 2025; no changes to proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93621,"accession_number":"0001213900-26-042468","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2026-04-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"iSpecimen reduces biospecimen shipping time by up to 85% with direct-to-customer model","event_type":"other_material","confidence":"high","bullets":["Domestic shipments now delivered in 1-2 days vs. 7-14 days previously, a 70-85% reduction.","Streamlined model reduces reliance on central hub, lowering overall shipping costs through fewer handoffs.","Expanded international partnerships in Europe and Eastern Europe for rare biospecimens, improving turnaround times.","CEO Katie Field notes positive customer feedback on delivery speed, quality, and care."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105409,"accession_number":"0001213900-26-027736","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"iSpecimen annual meeting adjourned repeatedly due to lack of quorum; next adjournment April 10, 2026","event_type":"other_material","confidence":"high","bullets":["Annual meeting originally convened Dec 31, 2025; no quorum, adjourned.","Reconvened Jan 23, 2026, Feb 13, 2026, and Mar 13, 2026; quorum still not present.","Next adjournment set for Apr 10, 2026 at 9:00 AM ET.","Record date remains Nov 3, 2025; proposals unchanged from proxy statement filed Nov 21, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105408,"accession_number":"0001213900-26-019354","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Siyun Yang resigns from iSpecimen board effective Feb 17, 2026","event_type":"leadership","confidence":"high","bullets":["Resignation not due to any disagreement with the Company on operations, policies or practices.","Yang served as independent director since February 2025.","She was a member of the Audit Committee and the Nominating and Corporate Governance Committee.","No replacement has been named as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105407,"accession_number":"0001213900-26-017963","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"iSpecimen adjourns annual meeting three times due to no quorum; next attempt March 13, 2026","event_type":"other_material","confidence":"high","bullets":["Dec 31, 2025 annual meeting adjourned for lack of quorum.","Reconvened Jan 23, 2026 and Feb 13, 2026, both also lacked quorum.","Next reconvened meeting scheduled March 13, 2026; record date remains Nov 3, 2025.","No changes to proposals from the original proxy statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105406,"accession_number":"0001213900-26-013265","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2026-02-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"iSpecimen completes SalesStack Milestone 2, launches live marketplace; procures 500 influenza samples","event_type":"other_material","confidence":"high","bullets":["Milestone 2 achieved: end-to-end system integration, legacy data migration, live marketplace at mp.ispecimen.com.","AI-assisted demand-supply matching now live; legacy AWS costs to be reduced from infrastructure sunset.","Collected 500 influenza swab samples in a few weeks for a customer research project.","Consistent CSF supply maintained; increased customer demand for FFPE and fresh frozen tissue.","Customer praised urine specimen quality and documentation, plans to cite iSpecimen in publications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105405,"accession_number":"0001213900-26-008215","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2026-01-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"iSpecimen adjourns annual meeting twice due to lack of quorum; next attempt Feb 13, 2026","event_type":"other","confidence":"high","bullets":["Annual Meeting adjourned on Dec 31, 2025 and again on Jan 23, 2026 due to no quorum.","Reconvened meeting scheduled for February 13, 2026; record date remains November 3, 2025.","Stockholders are asked to vote on proposals per the definitive proxy filed Nov 21, 2025.","Continued lack of quorum may delay shareholder decisions on key proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105401,"accession_number":"0001213900-26-005138","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K/A","filed_at":"2026-01-16T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"iSpecimen amends Series C Preferred Stock terms to add anti-dilution adjustment for reverse splits","event_type":"other_material","confidence":"high","bullets":["On Jan 16, 2026, iSpecimen filed amended Certificate of Designation for Series C Convertible Non-Voting Preferred Stock.","Amendment adjusts Conversion Price and Floor Price proportionately on any reverse stock split or share combination.","Approved by holders of majority of outstanding Series C Preferred Stock per Section 23 of original designation.","No other changes to terms, preferences, or privileges of Series C Preferred Stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105404,"accession_number":"0001213900-26-001264","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2026-01-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"iSpecimen 2025 annual meeting adjourned due to lack of quorum; reconvenes Jan 23, 2026","event_type":"other_material","confidence":"high","bullets":["Annual Meeting held Dec 31, 2025 adjourned because quorum was not achieved.","Meeting reconvened to Jan 23, 2026; record date remains Nov 3, 2025.","Company seeks additional time for stockholders to vote on proxy proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.35,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105403,"accession_number":"0001213900-26-001257","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2026-01-05T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"iSpecimen pays IR Agency $2M upfront for 4-month marketing consulting","event_type":"other_material","confidence":"high","bullets":["Aggregate cash fee of $2,000,000 paid upon execution from Series C Preferred Stock placement proceeds.","Four-month term beginning December 31, 2025, for marketing, advertising, and digital community-building services.","Consultant is not a broker-dealer and will not solicit investors or effect securities transactions.","Agreement may be terminated with or without cause; fees deemed earned upon receipt and non-refundable if client terminates.","Company funded the fee from net proceeds of its private placement of Series C Convertible Non-Voting Preferred Stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105402,"accession_number":"0001213900-26-000496","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["1.01","3.02","5.03","9.01"],"status":"ready","headline":"iSpecimen raises $5.5M via Series C Convertible Preferred Stock at $800/share","event_type":"other_material","confidence":"high","bullets":["Issued 6,875 shares of Series C Convertible Non-Voting Preferred at $800/share for $5.5M aggregate.","Conversion price set at 85% of prior day's closing price, floor at $0.0681 per share.","Shares are senior to common on liquidation and carry no voting rights; registration rights granted.","E.F. Hutton acted as exclusive placement agent; lock-up agreements with officers/directors for 180 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121686,"accession_number":"0001213900-25-116663","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2025-12-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"iSpecimen regains Nasdaq compliance on stockholders' equity, matter closed","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on Nov 28, 2025 confirming compliance with continued listing requirements.","Previously disclosed deficiency on June 4, 2025 for minimum equity, market value, or net income.","Based on Q3 2025 10-Q showing stockholders' equity of $3,072,711, Staff determined compliance and closed matter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121685,"accession_number":"0001213900-25-113708","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"iSpecimen receives Nasdaq deficiency notice for bid price below $1.00; cure deadline May 18, 2026","event_type":"regulatory","confidence":"high","bullets":["Notice received Nov 19, 2025; stock continues trading under ISPC with no immediate delisting.","Company has 180 calendar days, until May 18, 2026, to regain compliance.","To cure, closing bid price must be at least $1.00 for ten consecutive business days.","If not cured by May 18, 2026, an additional 180-day period may be available if other listing criteria are met.","Options include a reverse stock split; failure to cure could lead to delisting and appeal rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121684,"accession_number":"0001213900-25-107647","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"iSpecimen appoints Katharyn Field as CEO, replacing Robert Bradley Lim; adds independent director Tommy Lee.","event_type":"leadership","confidence":"high","bullets":["Katharyn Field appointed CEO, Secretary, and Treasurer effective Nov 7, 2025; she continues as President.","Robert Bradley Lim resigned as CEO, Secretary, Treasurer and from board; no disagreement cited.","Arphing (Tommy) Lee appointed as independent director, joining Audit and Nominating/Governance Committees.","Board committees reconstituted; Field now holds three officer titles."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121683,"accession_number":"0001213900-25-104942","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"iSpecimen stockholders approve reverse stock split, authorized share increase, and equity line of credit","event_type":"other_material","confidence":"high","bullets":["Reverse stock split approved at ratio from 1:10 to 1:100; Board to set exact ratio.","Authorized shares increased from 250M to 1B; 1,370,770 voted for.","Private financings up to >19.99% of shares at sub-minimum price approved for Nasdaq compliance.","Convertible securities amended to raise conversion price floor from 50% to 80% of lowest VWAP.","Equity line of credit approved allowing issuance >19.99% of shares at below-minimum price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138363,"accession_number":"0001213900-25-084497","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"iSpecimen approached by crypto companies for $200M Solana treasury initiative","event_type":"other_material","confidence":"high","bullets":["iSpecimen has been approached by several crypto firms for opportunities in tokenized real-world assets and top cryptocurrencies.","Company continues meetings to build a Solana-based treasury program of up to $200 million.","Plans to purchase SOL, including locked SOL at a discount, and stake holdings to generate yield.","Will fund treasury primarily from capital raised; intends to source external treasury management expertise.","Strategy includes HODL approach, staking, liquid staking tokenization, and limited spot trading."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138362,"accession_number":"0001213900-25-079167","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2025-08-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"iSpecimen completes Milestone 1 of digital transformation with Salestack platform","event_type":"other_material","confidence":"high","bullets":["Completed Milestone 1 installation of Salestack platform and modern infrastructure for iSpecimen Marketplace.","Milestone 1 focused on Infrastructure-as-Code, unified storage/workflows, and future-ready multi-cloud architecture.","Moving to Milestone 2 (Integration) to connect all business operations for end-to-end efficiency.","Expected benefits include improved reliability, enhanced security, and accelerated innovation cycles.","CEO Robert Lim states milestone sets stage for long-term shareholder value creation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138361,"accession_number":"0001213900-25-073069","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"iSpecimen plans $200M Solana-based digital asset treasury, hires BlockArrow","event_type":"other_material","confidence":"high","bullets":["iSpecimen to build up to $200M corporate treasury reserve on Solana blockchain ecosystem.","Retained WestPark Capital as advisor; contracted BlockArrow for digital asset strategy and management.","Treasury will use cold storage, insured custody via Coinbase Custody, and institutional risk controls.","CEO Rob Lim says initiative aligns with decentralized infrastructure and digital asset future.","Company plans to diversify future digital treasury across high-performing crypto assets for liquidity and growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138360,"accession_number":"0001213900-25-072070","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"iSpecimen raises $1.75M in private placement of common stock and pre-funded warrants","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$1.75M from 1,559,828 shares (or pre-funded warrants) at $1.122/share; closed August 4, 2025.","$500K of net proceeds allocated to marketing/advertising services from IR Agency LLC; remainder for working capital.","WestPark Capital acting as exclusive placement agent received 4% cash commission on gross proceeds.","Company to file resale registration statement within 15 calendar days of closing per Registration Rights Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138359,"accession_number":"0001213900-25-067772","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2025-07-25T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"iSpecimen closes $4M public offering of common stock and pre-funded warrants","event_type":"other_material","confidence":"high","bullets":["Sold 5,714,283 securities (1,482,644 shares + 4,231,639 pre-funded warrants) at $0.70/share for gross $4M.","Net proceeds of ~$3.53M after underwriting discounts and offering expenses; closed July 25, 2025.","Plans to use $1.5M for marketing/advertising via IR Agency LLC and $1M for software milestone with Sales Stack Solutions.","WestPark Capital acted as sole book-runner; offering made under effective Form S-1 (File 333-286958).","Pre-funded warrants exercisable immediately at $0.0001, with 4.99% beneficial ownership limitation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138358,"accession_number":"0001213900-25-062804","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2025-07-10T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"iSpecimen amends bylaws to reduce shareholder quorum to 34% from majority","event_type":"other","confidence":"high","bullets":["Quorum threshold reduced from a majority to 34% of voting power.","Amendment adopted on July 9, 2025; Third Amended and Restated Bylaws filed.","No other changes to bylaws or fiscal year disclosed.","Governance change effective immediately upon adoption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155810,"accession_number":"0001213900-25-057284","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"iSpecimen directors Paolone and Brooks resign; Lau appointed to board","event_type":"leadership","confidence":"high","bullets":["Richard J. Paolone resigned as director and Chairman effective June 18; no disagreement involved.","John L. Brooks III resigned as director effective June 18; he previously chaired the Audit Committee.","Anthony Lau appointed director effective June 20; also joins Audit, Compensation, and Nominating Committees.","Lau is CEO/CFO of Remington Resources; brings public company governance and financial reporting experience.","Board committees reorganized: Lau chairs Audit, Yang chairs Compensation, Dhaliwal chairs Nominating."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155809,"accession_number":"0001213900-25-051593","cik":1558569,"company_name":"iSpecimen Inc.","ticker":"ISPC","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"iSpecimen receives Nasdaq delisting notice for failing to meet minimum stockholders' equity requirement","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on June 4, 2025 regarding non-compliance with Listing Rule 5550(b)(1) requiring minimum $2.5M stockholders' equity.","As of March 31, 2025, stockholders' equity was $1,668,513, below the $2.5M threshold; no alternative listing criteria met.","Company has 45 days to submit a compliance plan; if accepted by Nasdaq, may receive up to 180-day extension to regain compliance.","If plan not accepted or compliance not regained, Nasdaq may delist the common stock; Company can appeal to a Hearings Panel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}